DPLG3

DPLG3 is a specific chymotryptic-like β5i subunits inhibitor, with an IC50 of 4.5 nM. DPLG3 inhibits mouse i-20S with IC50 of 9.4 nM. DPLG3 downregulates the protein levels of NF-κB p50 and p65. DPLG3 can be used for immune disease research[1][2][3].

Product Specifications

CAS Number

[1801379-22-5]

UNSPSC

12352209

Target

NF-κB; Proteasome

Type

Peptides

Related Pathways

Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/dplg3.html

Purity

99.18

Solubility

10 mM in DMSO

Smiles

FC(C=C1)=CC=C1C[C@H](NC([C@H](CC(NOC(C)(C)C)=O)NC(CCC2=CC=CC=C2)=O)=O)C(NCC3=CC=CC4=C3C=CC=C4)=O

Molecular Formula

C37H41FN4O5

Molecular Weight

640.74

References & Citations

[1]Moallemian R, et al. Immunoproteasome inhibitor DPLG3 attenuates experimental colitis by restraining NF-κB activation. Biochem Pharmacol. 2020 Jul;177:113964.|[2]Sula Karreci E, et al. Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proc Natl Acad Sci U S A. 2016 Dec 27;113 (52) :E8425-E8432. |[3]Basler M, et al. On the role of the immunoproteasome in transplant rejection. Immunogenetics. 2019 Mar;71 (3) :263-271.